Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity
Modifying patients’ T-cells with mRNA to express a chimeric antigen receptor (rCAR-T therapy) a novel approach to treat myasthenia gravis and other autoimmune diseases. GAITHERSBURG, Md.--(BUSINESS WIRE)-- Cartesian Therapeutics, a...
Read more